Xconomy | Boston - Business + Technology in the Exponential Economy

Biotech, Arthritis, Layoffs

CombinatoRx Cuts 30 More Jobs, Wiping out Two-Thirds of Staff in Last Month

Luke Timmerman 11/20/08

CombinatoRx, the Cambridge, MA-based biotech company, said this afternoon it is cutting 30 more jobs, which means it has now eliminated two-thirds of its staff since its lead drug candidate for arthritis failed in a clinical trial in early October. The company (NASDAQ: CRXX), which will be left with 55 employees, should have enough cash to operate without raising more capital from investors for four years, the company said. We’ve updated our Boston Tech Layoff Tracker accordingly.

Luke Timmerman is the National Biotechnology Editor for Xconomy. You can e-mail him at ltimmerman@xconomy.com, call 206-624-2374, or follow him on Twitter at http://twitter.com/ldtimmerman.


Links to This Post

Add Your Thoughts



You will have 10 minutes to edit your post after you press publish.

Comments may be edited for clarity and length, rejected, or deleted. By clicking "Publish," you are agreeing to these Terms and Conditions.

    

Business, life sciences, and technology news — covering Boston, Seattle, San Diego, and beyond.

© 2007-2009, Xconomy, Inc. XCONOMY is a registered service mark of Xconomy, Inc. All rights reserved.
Site designed by Matthew Bouchard, produced by Andrew Koyfman, and powered by WordPress.